title: MDR1 gene expression in endometrial carcinoma.
abstract: The objective of the present study was to determine the MDR1 gene expression in endometrial cancer. Twenty-six newly diagnosed patients with endometrial carcinoma were included in this study. Patients were treated with surgery followed by adjuvant radiotherapy. Four- to six-micrometer sections of the archival paraffin-embedded blocks were cut, deparaffinized, and stained by immunohistochemical technique using P-glycoprotein dye. Endothelial cell staining was used as the positive control of the dye. Immunostaining was categorized from 0% to 100% based on the percentage of cells stained by examining 3-4 high-power fields. The mean P-glycoprotein immunoreactivity for the whole study group was 17 +/- 25% (0-90). Tauhe mean P-glycoprotein immunoreactivity was 21 +/- 26% (0-90) for the endometrioid histology and 6 +/- 13% (0-30) for the clear cell histology. P-glycoprotein immunoreactivity was not detected in a case of mucinous histologic subtype. There was a significant negative correlation between age and P-glycoprotein immunoreactivity (r = -0.530, P = 0.005). The P-glycoprotein immunoreactivity was found to be 30% positive in only one case of clear cell histologic type out of five. However, P-glycoprotein immunoreactivity was not significantly lower in clear cell histologic subtype compared with endometrioid subtype of endometrial cancer (P = 0.116). P-glycoprotein immunoreactivity was found to be 0% in grade 1 (n = 2), 22 +/- 28% in grade 2 (n = 17), and 8 +/- 14% in grade 3 (n = 7) patients (P = 0.273). Premenopausal patients were found to have a significantly higher P-glycoprotein expression (40 +/- 33)% vs. 11 +/- 20%, P = 0.04). P-glycoprotein immunoreactivity was found to be less with advanced age in endometrial carcinoma. However, premenopausal patients were found to have a significantly higher P-glycoprotein expression.
authors.affiliation: Department of Obstetrics and Gynecology, Ege University Faculty of Medicine, Izmir, Turkey, Izmir, Turkey. terek@med.ege.edu.tr
authors.forename: M C
authors.initials: MC
authors.lastname: Terek
authors.forename: O
authors.initials: O
authors.lastname: Zekioglu
authors.forename: F
authors.initials: F
authors.lastname: Sendag
authors.forename: F
authors.initials: F
authors.lastname: Akercan
authors.forename: A
authors.initials: A
authors.lastname: Ozsaran
authors.forename: Y
authors.initials: Y
authors.lastname: Erhan
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D016889:Endometrial Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism / Q000473:pathology / Q000628:therapy
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D014408:Biomarkers, Tumor